Annual Report 2020

9. By submitting an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the AGM and/ or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member’s personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the AGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the “Purposes”), (ii) warrants that where the member discloses the personal data of the member’s proxy(ies) and/or representative(s) to the Company (or its agents), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member’s breach of warranty. EXPLANATORY NOTES: A. Audited Financial Statements together with the Reports of the Directors and Auditors thereon for the financial year ended 31 December 2020 This Agenda item is meant for discussion only in accordance with Sections 248(2) and 340(1) of the Companies Act, 2016 (“the Act”). The audited financial statements do not require the formal approval of shareholders and hence, the matter will not be put forward for voting. B. To approve the Non-Executive Directors’ Remuneration for the period from 23 July 2021 until the next Annual General Meeting (“AGM”) of the Company to be held in the year 2022 (Ordinary Resolution 1) The Nomination and Remuneration Committee had recommended and the Board of Directors (“Directors”) affirmed that the Non-Executive Directors’ Remuneration for the period from 23 July 2021 until the next AGM of the Company to be held in the year 2022 shall remain unchanged as per the financial year ended 31 December 2020, as shown below: Non-Executive Directors’ Fees (per annum) Non-Executive Chairman (RM) Per Non-Executive Director/Per other Committee Member (RM) Board of Directors N/A 262,500 Audit Committee 75,000 60,000 Nomination and Remuneration Committee 55,000 35,000 Safety Review Board 55,000 35,000 Risk Management Committee 55,000 35,000 Non-Executive Directors’ Benefits (per attendance by each Director or committee member) Board of Directors (RM) Board Committees (RM) Meeting allowance 2,000 2,000 Other Non-Executive Directors’ Benefits Insurance premiums on medical coverage, and other claimable expenses incurred in the course of carrying out their duties. Up to a total amount of RM100,000 for all Non-Executive Directors. The shareholders’ approval being sought under Ordinary Resolution 1 is for the payment of the remuneration to the Non- Executive Directors of the Company for the period from 23 July 2021 up to the next AGM of the Company to be held in the year 2022 in accordance with the remuneration structure as set out above, and to authorise the Board of Directors to disburse the fees on a monthly basis. 23 ANNUAL REPORT 2020